Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 570 JPY -3.72% Market Closed
Market Cap: 8.4B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Perseus Proteomics Inc
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Cash Equivalents
ÂĄ1.5B
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Cash Equivalents
ÂĄ14B
CAGR 3-Years
0%
CAGR 5-Years
14%
CAGR 10-Years
11%
PeptiDream Inc
TSE:4587
Cash Equivalents
ÂĄ50.4B
CAGR 3-Years
60%
CAGR 5-Years
43%
CAGR 10-Years
31%
Takara Bio Inc
TSE:4974
Cash Equivalents
ÂĄ40B
CAGR 3-Years
7%
CAGR 5-Years
17%
CAGR 10-Years
8%
Pharma Foods International Co Ltd
TSE:2929
Cash Equivalents
ÂĄ11.8B
CAGR 3-Years
2%
CAGR 5-Years
27%
CAGR 10-Years
22%
C
Cuorips Inc
TSE:4894
Cash Equivalents
ÂĄ5.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
8.4B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
732.02 JPY
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Cash Equivalents?
Cash Equivalents
1.5B JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Cash Equivalents amounts to 1.5B JPY.

What is Perseus Proteomics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
7%

Over the last year, the Cash Equivalents growth was -37%. The average annual Cash Equivalents growth rates for Perseus Proteomics Inc have been 13% over the past three years , 7% over the past five years .

Back to Top